Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.
Eur J Cancer
January 2025
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Radiation Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Background: About 15-20 % of patients with metastatic breast cancer (mBC) can experience oligoprogressive disease (OPD) in ≤ 5 sites of disease. Patients with OPD may benefit from metastasis-directed stereotactic radiotherapy (SBRT) to all sites of cancer progression while maintaining the same systemic treatment, aiming to prolong the time to next systemic treatment (NEST). This study aims to assess the outcomes provided by this multimodal strategy.
View Article and Find Full Text PDFMetastatic Malignant Melanoma of Brain: A Rare Case Report.
Asian J Neurosurg
December 2024
Department of Neurosurgery, Sawai Man Singh Medical College, Jaipur, Rajasthan, India.
Malignant melanoma is third most common cause of brain metastasis after lung and breast cancer. Most patients with brain metastases from malignant melanoma are diagnosed after treatment for known extracranial metastases and have a poor outcome despite various local and systemic therapeutic approaches. Here we discuss an unusual case of a 61-year-old male patient who presented with a brain metastasis as the initial disease presentation and the presumed primary lesion was later found in the gastrointestinal tract and the scalp.
View Article and Find Full Text PDFMesenchymal Tumor Management: Integrating Surgical and Non-Surgical Strategies in Different Clinical Scenarios.
Cancers (Basel)
August 2024
Sarcoma, Melanoma and Rare Tumors Surgery Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
Article Synopsis
- - Mesenchymal tumors, which arise from mesenchymal cells, can be benign or malignant and often require complex surgical procedures for treatment; however, the COVID-19 pandemic has led to a need for non-surgical alternatives due to limited surgical resources.
- - This review discusses various non-surgical treatments, including active surveillance, cryoablation, and tyrosine kinase inhibitors, aimed at improving surgical outcomes, serving as pre-surgery bridges, or providing non-curative options when surgery isn't feasible.
- - The Sarculator tool is mentioned as a means to personalize treatment plans for high-risk sarcoma patients, emphasizing the importance of a multidisciplinary approach in referral centers to optimize treatment strategies.
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
J Nucl Med
August 2024
Department of Health Sciences, University of Genova, Genova, Italy.
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials. We retrospectively identified oligorecurrent PCa patients who had 5 or fewer nodal, bone, or visceral metastases detected by choline or prostate-specific membrane antigen (PSMA) PET/CT and who underwent MDT stereotactic body radiotherapy with or without systemic therapy in 8 tertiary-level cancer centers.
View Article and Find Full Text PDFStereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi).
Int J Gynecol Cancer
August 2024
Division of Radiation Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Objective: Poly (ADP-ribose) polymerase inhibitors (PARPi) have become a new standard of care for the maintenance treatment of advanced epithelial ovarian cancer. This study aims to evaluate the efficacy and safety of combining stereotactic body radiotherapy with PARPi continuation as a strategy to treat ovarian cancer oligoprogression on PARPi.
Methods: This is a multicenter retrospective study including ovarian cancer patients treated with stereotactic body radiotherapy and PARPi continuation for oligoprogression under PARPi maintenance therapy between June 2012 and May 2023 in three Italian centers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!